Diabetic macular edema (DME) is a complication of diabetes ... His research interests include diabetic retinopathy, macular degeneration, retinal vein occlusions, and infectious retinitis.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

such as retinopathy of prematurity (ROP), to their later years, including diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO) and wet age ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

About Diabetic Macular Edema (DME) DME is the leading cause ... DME is an irreversible and progressive complication of diabetic retinopathy and is related to consistently having high blood sugar ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

Pars plana vitrectomy is a safe and effective surgery that is essential in the treatment of a variety of posterior segment ...

About Diabetic Macular Edema (DME) DME is the leading cause of visual loss ... DME is an irreversible and progressive complication of diabetic retinopathy and is related to consistently having high ...

Oculis Holding completes enrollment in both DIAMOND phase 3 clinical trials of OCS-01 in diabetic macular edema: Zug, Switzerland Monday, April 14, 2025, 15:00 Hrs [IST] Oculis Ho ...